Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288203 · ClinicalTrials.gov registry record · Phase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
A Phase 2 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT07288203: Recruiting Phase 2 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
NCT07288203 is a Phase 2 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 100 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (22% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07288203, a Phase 2 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Primary Outcome
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC
Conditions Studied
Interventions
- BIOLOGICAL Lifileucel
Study Locations (5)
Tennessee
- Sarah Cannon Research Institute - Nashville
Queensland
- Greenslopes Private Hospital - Greenslopes
Ontario, Canada
- Princess Margaret Cancer Centre - Toronto
Quebec, Canada
- Centre Hospitalier de l'Universite de Montreal - Montral
Other
- Royal Marsden Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2033-12 |
| Phase | Phase 2 |
What NCT07288203 shows while recruiting
NCT07288203 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (22% higher).
The record links to 3 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Lifileucel is the first listed.
NCT07288203 lists 5 locations in 5 states (Tennessee, Queensland, Ontario, Canada).
Frequently Asked Questions
What is clinical trial NCT07288203 about?
NCT07288203 is a clinical study titled "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma". This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
What is the current status of trial NCT07288203?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-11-28. Estimated completion is 2033-12.
What conditions does trial NCT07288203 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma (Skin Cancer).
What interventions are being tested in trial NCT07288203?
The interventions under investigation include: Lifileucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT07288203?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288203 being conducted?
This trial has 5 study locations across Tennessee, Queensland, Ontario, Canada, Quebec, Canada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07288203's enrollment target sits among peer trials
100 20th of 91 higher than 72 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI